This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets used in this study are available from the corresponding author upon reasonable request.
References
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Prim. 2016;2:16010.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–205.
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988–1005.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
Grossmann V, Schnittger S, Poetzinger F, Kohlmann A, Stiel A, Eder C, et al. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia. Leukemia. 2013;27:1933–6.
Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, et al. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Adv. 2018;2:2879–89.
Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, et al. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Adv. 2020;4:4623–31.
Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun. 2021;12:1808.
Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25:1239–48.
Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116:923–9.
Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, et al. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022;15:152.
Guerrero S, Casanova I, Farré L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750–6.
Matsuo H, Yoshida K, Nannya Y, Ito Y, Inagami A, Ito N, et al. Distinctive clonal evolution pattern and prognostic significance of the clonality of KRAS mutations in KMT2A-rearranged acute myeloid leukemia. HemaSphere. 7:e51775a7, https://doi.org/10.1097/01.HS9.0000969016.51775.a7.
Acknowledgements
The authors thank Dr. Hiroo Ueno (Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan) for supporting sequencing analysis. This work was supported by a Grant-in-Aid from the Agency for Medical Research and Development (Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), Project for Cancer Research and Therapeutic Evolution (P-CREATE), and Practical Research for Innovative Cancer Control) and JSPS KAKENHI (JP19K16832, JP22K08475, and JP23K07264). Supercomputing resources were provided by the Human Genome Center, Institute of Medical Science, University of Tokyo. We thank all participating doctors and patients who were involved in the JCCG AML-99/AML-05/AML-12 studies.
Author information
Authors and Affiliations
Contributions
SI, KY, KS, and H Matsuo analyzed the clinical and sequencing data; NI and MT helped with the analysis; YN, GY, ST, NS, and YH performed sequencing; Y Shiozawa, Y Shiraishi, KC, AO, HT, and SM developed sequence data processing pipelines; YK, HG, H Moritake, KT, EI, NK, DT, TT, AT, JT, and SA collected clinical samples; KY, MN, SA, SO, and H Matsuo supervised the project. SI, KY, KS, and H Matsuo wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
SO: Leadership position/advisory role for Eisai, Chordia Therapeutics. Stockholder in: Asahi Genomics. Grant/Research funding from Chordia Therapeutics, Otsuka Pharmaceutical, Eisai. The remaining authors declare no competing financial interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Iyoda, S., Yoshida, K., Shoji, K. et al. KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia. Leukemia (2024). https://doi.org/10.1038/s41375-024-02244-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41375-024-02244-4